SFTPD

Across TCGA pan-cancer cohorts, SFTPD Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SFTPD data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher SFTPD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SFTPD expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, KIRC, and HNSC are the cancer types where SFTPD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.055	0.708	<.001	36	view →
KIRC	OS	Median	All	0.170	0.811	.001	24	view →
HNSC	OS	Median	All	0.168	0.661	.004	12	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	6	view →
UCEC	DFS	Median	All	0.951	0.620	.027	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SFTPD–SCLC (OS)

Open the SCLC breakdown →